← Browse by Condition
Medical Condition

portal hypertension

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 4, Phase 3

Hypertension remains the most common treatable cardiovascular risk factor globally, yet blood pressure control rates remain suboptimal despite multiple effective drug classes. Clinical trials now investigate novel mechanisms including aldosterone synthase inhibitors, renal denervation devices, and RNA-based therapies targeting angiotensinogen to achieve durable pressure reduction with minimal pill burden.

Active research includes zilebesiran (RNA interference targeting angiotensinogen), baxdrostat (aldosterone synthase inhibitor), ultrasound renal denervation (Symplicity HTN-4), and resistant hypertension approaches combining SGLT2 inhibitors with MRA spironolactone. Ambulatory blood pressure monitoring is increasingly used as the primary endpoint instead of clinic readings.

Frequently Asked Questions — portal hypertension Clinical Trials

How many clinical trials are currently recruiting for portal hypertension?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for portal hypertension, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for portal hypertension?
portal hypertension research spans Phase 3 (1 trial), Phase 4 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a portal hypertension clinical trial?
Eligibility criteria for portal hypertension trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 3
1
Phase 4
2
Top Sponsors
University Hospital, Bonn 1 trial
Asian Institute Of Medical Sciences 1 trial
Chinese University of Hong Kong 1 trial
Thomas Jefferson University 1 trial

Recruiting Clinical Trials

NCT04393519
Recruiting
Non-invasive Evaluation Program for TIPS and Follow Up Network 2 (NEPTUN2)
Enrollment
1,000 pts
Location
Germany
Sponsor
University Hospital, Bonn
View Trial →
NCT07521332 Phase 4
Recruiting
Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis
Enrollment
220 pts
Location
Pakistan
Sponsor
Asian Institute Of Medical Sci...
View Trial →
NCT06449339 Phase 4
Recruiting
Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease
Enrollment
474 pts
Location
Hong Kong
Sponsor
Chinese University of Hong Kon...
View Trial →
NCT05470205 Phase 3
Recruiting
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
Enrollment
660 pts
Location
United States, Switz...
Sponsor
Thomas Jefferson University
View Trial →

Related Conditions

cirrhosis (1) esophageal and gastric varices (1) ascites (1) hepatic encephalopathy (1) portal vein thrombosis (1) hepatic decompensation (1) advanced chronic liver disease (1) liver diseases (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology